Following the introduction of immune checkpoint inhibitors (ICIs), more treatment options are becoming available in non-small cell lung cancer (NSCLC), and many patients are now treated with first- or second-line ICIs. Therefore, it is becoming increasingly important in clinical practice to establish the optimal treatment after ICI therapy ± chemotherapy. Preliminary data from two published datasets suggest that patients who progress on previous ICI therapy may benefit from treatment with nintedanib* plus docetaxel.
Nintedanib plus docetaxel after chemotherapy and ICI therapy in the nintedanib named patient use programme
In this retrospective analysis of patients in Spain who participated in the nintedanib named patient use programme, 11 patients received nintedanib plus docetaxel after chemotherapy and ICI therapy (nivolumab, n=3; pembrolizumab, n=4; atezolizumab, n=4).1 Treatment with nintedanib plus docetaxel was associated with an objective response rate (ORR) of 36%, a disease control rate (DCR) of 82% and a median progression-free survival (PFS) of 3.2 months.1
VARGADO Cohort B: nintedanib plus docetaxel after first-line chemotherapy and second-line ICI therapy
VARGADO is a prospective, non-interventional study of nintedanib plus docetaxel after first-line chemotherapy in the routine clinical treatment of patients with locally advanced, metastatic or locally recurrent adenocarcinoma NSCLC.2
In the first interim analysis of Cohort B of VARGADO, 22 patients received nintedanib plus docetaxel after first-line chemotherapy (± bevacizumab) and second-line treatment with nivolumab (n=17) or pembrolizumab (n=5).2 At the time of the interim analysis (data cut-off: 1 August 2018), median duration of follow-up was 6.0 months (95% confidence interval [CI]: 3.5–8.8).2 Median PFS was 5.5 months (95% CI: 1.9–8.7; n=21) and overall survival data were not yet mature; ORR was 58% (n=7/12) and DCR was 83% (n=10/12).2
The most common Grade ≥3 nintedanib-related adverse events were stomatitis (14%), decreased white blood cell count (14%) and febrile neutropenia (9%).2,3
Corral, J et al. Clin Transl Oncol 2019. Feb 15. doi: 10.1007/s12094-019-02053-7 [Epub ahead of print].
Grohé C, et al. Future Oncol 2019. Jul 8. doi: 10.2217/fon-2019-0262 [Epub ahead of print].
Grohé C, et al. Poster presented at ESMO I-O 2018 (Poster 55P).
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.
Page last updated: October 2019
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue